Johnson & Johnson raises 2026 sales guidance after Q2 drug revenue hit $25.3 billion

Statements (5)

1. ▲ Bullish

   Johnson & Johnson raised its full-year guidance.

   deraktionaer.deOct 13, 2026 11:19 UTCHigh importance
2. ▲ Bullish

   Johnson & Johnson beats estimates and raises 2026 guidance

   finance.yahoo.comOct 13, 2026 11:00 UTCHigh importance
3. ● Neutral

   Johnson & Johnson raises earnings guidance despite a stumble in the pharma sector.

   barrons.comOct 13, 2026 10:51 UTC
4. ▲ Bullish

   Johnson & Johnson is raising its earnings outlook following a significant increase in quarterly drug sales.

   bloomberg.comOct 13, 2026 10:20 UTCHigh importance
5. ▲ Bullish

   Johnson & Johnson raised its 2026 outlook after second-quarter sales increased 6.6% to $25.3 billion.

   insidermonkey.comOct 7, 2026 21:13 UTCHigh importance